Vivos Therapeutics (VVOS) CEO Ronald Huntsman Buys $50K in PIPE

What Happened
Ronald Huntsman, CEO of Vivos Therapeutics (VVOS), participated indirectly in the company’s PIPE offering on June 30, 2026, through V-Co Investors 4 LLC. His indirect interest represented about $50,000 of V-Co 4’s purchase, corresponding to 85,910 units reported as Series A Convertible Preferred Stock and warrants to purchase 85,910 shares of common stock. The filing lists the per-unit price as $0.58 (the footnote clarifies the PIPE per‑unit price as $0.582). The warrants are exercisable at $0.456 per share through June 30, 2031; the preferred is convertible at the holder’s election and has no expiration date.

Key Details

• Transaction date: June 30, 2026 (reported on Form 4 filed 2026-09-18; filing flagged as late)
• Reported acquisition: 85,910 preferred units and 85,910 warrants at ~$0.58 per unit, total pecuniary interest ≈ $50,000
• Derivative terms: warrants exercisable at $0.456/share through 06/30/2031; preferred convertible anytime (subject to beneficial‑ownership cap)
• Record ownership: the securities are held of record by V-Co Investors 4 LLC; Huntsman acquired a membership interest in V-Co 4 and disclaims beneficial ownership except to the extent of his pecuniary interest (Footnote F2). Additional shares are held by Coronado V Partners, LLC, of which he is a member/manager (Footnote F1).
• Options note: filing also references employee stock options with exercise prices $2.38–$81.75 and expirations 2027–2034, and the expiry of 5,001 options on 06/26/2026 (Footnote F3).
• Shares owned after transaction: not specified for direct beneficial ownership in the Form 4; recorded securities are held by V-Co 4.

Context

• This was a purchase via an investment vehicle (V-Co 4) in a PIPE offering, not an open‑market buy. The reported interest is indirect and limited to Huntsman’s pecuniary stake in that vehicle, per the filing.
• The Form 4 was filed late (reported 2026-09-18 for a 2026-06-30 transaction); late filings can reduce the timeliness of public disclosure but do not by themselves change the reported transaction details.